Table A3.

Univariate and Multivariate Analysis of Cofactors Associated With TTP

Cofactor	Analysis of Progression-Free Survival
	Univariate			Multivariate
	P	HR	95% CI	P	HR	95% CI
KIT mutation
Exon 9	.0022	1.82	1.24 to 2.68	.0008	2.07	1.35 to 3.16
WT	.0051	1.53	1.14 to 2.06	.0002	1.85	1.34 to 2.56
Treatment*	.69	1.05	0.83 to 1.32	.18	1.18	0.93 to 1.50
Sex, male	.06	1.25	0.99 to 1.57	.007	1.41	1.10 to 1.82
Age, by decades	.78	0.99	0.90 to 1.08	.74	1.02	0.93 to 1.11
Zubrod performance†	1.6 × 10−6	2.14	1.57 to 2.92	8.1 × 10−5	2.02	1.42 to 2.87
ANC	.0061	1.07	1.02 to 1.12	.10	1.04	0.99 to 1.10
HGB	.0061	0.92	0.86 to 0.98	.21	0.96	0.89 to 1.03
Primary tumor type‡	.61	1.06	0.84 to 1.35	.19	1.19	0.92 to 1.54

Abbreviations: TTP, time to progression; HR, hazard ratio; WT, wild type; ANC, absolute neutrophil count; HGB, hemoglobin.

^*Treatment of imatinib 400 mg/d v 800 mg/d.

^†Performance score of 0 to 1 v 2 to 3.

^‡Gastric v nongastric tumor type.